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At present there are limited therapeutic interventions for patients with mitochondrial myopathies. Exercise
training has been suggested as an approach to improve physical capacity and quality of life but it is uncertain
whether it offers a safe and effective treatment for patients with heteroplasmic mitochondrial DNA (mtDNA)
mutations. The objectives of this study were to assess the effects of exercise training and detraining in eight
patients with single, large-scalemtDNA deletions to determine: (i) the efficacy and safety of endurance training
(14 weeks) in this patient population; (ii) to determine the effect of more prolonged (total of 28 weeks) exercise
training upon muscle and cardiovascular function and (iii) to evaluate the effect of discontinued training
(14 weeks) upon muscle and cardiovascular function. Our results show that: (i) 14 weeks of exercise training
significantly improved tolerance of submaximal exercise and peak capacity for work, oxygen utilization and
skeletal muscle oxygen extraction with no change in the level of deleted mtDNA; (ii) continued training for an
additional 14 weeks maintained these beneficial adaptations; (iii) the cessation of training (detraining) resulted
in loss of physiological adaptation to baseline capacity with no overall change in mutation load. Patients’ self
assessment of quality of life as measured by the SF-36 questionnaire improved with training and declined with
detraining. Whilst our findings of beneficial effects of training on physiological outcome and quality of life
without increases in the percentage of deleted mtDNA are encouraging, we did not observe changes in
mtDNA copy number. Therefore there remains a need for longer term studies to confirm that endurance
exercise is a safe and effective treatment for patients with mitochondrial myopathies. The effects of detraining
clearly implicate physical inactivity as an important mechanism in reducing exercise capacity and quality of life
in patients with mitochondrial myopathy.
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Introduction
Defects of mitochondrial oxidation are important causes of
neurological disease (Zeviani and Di Donato, 2004). The
clinical features in these patients are highly variable with
both neurological and systemic involvement, although
neurological features often predominate (McFarland et al.,
2002). One of the best characterized neurological features is
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the muscle involvement, whichmay be severe in some patients
and associated with significant fatigability and weakness.
The molecular defect in adult patients with mitochondrial
myopathies commonly involves the mitochondrial genome,
with either single, large-scale deletions or point mutations
detected (Taylor and Turnbull, 2005). Since there are
multiple copies of the mitochondrial genome in individual
muscle fibres, these defects can be either homoplasmic
(all copies of the genome mutated) or heteroplasmic (with a
mixture of wild-type and mutated copies in the same muscle
fibre). In the presence of heteroplasmy there is typically a
threshold level of mutated mitochondrial DNA (mtDNA)
required before a biochemical defect is observed. Since
there is variation among different muscle fibres in the
amount of mutated mtDNA, this leads to a mosaic picture
of respiratory chain deficiency in muscle biopsies. This is
best detected using histochemical techniques for cytochrome
c oxidase (COX), (which has three catalytic subunits
encoded by the mitochondrial genome) and succinate
dehydrogenase (SDH) (all subunits encoded by the nuclear
genome) (Sciacco and Bonilla, 1996).
At present there are limited therapeutic interventions for
patients with mitochondrial myopathies (Chinnery and
Bindoff, 2003). Exercise training has been suggested as an
approach to improve physical capacity and quality of life but
whether it offers a safe and effective treatment for patients
with heteroplasmic mtDNA mutations is currently uncer-
tain. Endurance training was proposed as a therapeutic
strategy to improve severe exercise intolerance in patients
with high levels of mutation within skeletal muscle
(Taivassalo et al., 1996, 1998). The rationale was 2-fold: to
counter adverse physiological effects of deconditioning
caused by habitual avoidance of activities that provoke
symptoms of fatigue; and to ameliorate the disease process
by promoting an increase in mitochondrial biogenesis and
muscle oxidative capacity. While adaptations to such
training are well-established in healthy humans, effects of
endurance training in the unique setting of mitochondrial
heteroplasmy are difficult to predict. The goal of training in
this case is to promote expansion of wild-type mtDNA, but
equal or greater expansion of mutant mtDNA could also
occur.
Studies of endurance training in patients with various
heteroplasmic mtDNA mutations have demonstrated
increased exercise and oxidative capacity associated with
an improved quality of life (Taivassalo et al., 1997, 1998,
2001; Siciliano et al., 2000; Cejudo et al., 2005). However,
the only study to examine the effects of endurance training
on the proportion of mutant versus wild-type mtDNA
(Taivassalo et al., 2001) found that, despite improved
exercise and mitochondrial oxidative capacity, the percen-
tage of mutant mtDNA increased in over half of the subjects,
including patients with various heteroplasmic mtDNA
mutations (single, large-scale deletions and point mutations
affecting tRNA or protein-coding genes). These findings
were interpreted to suggest that the overall volume of
wild-type mtDNA increased but that levels of mutant
mtDNA increased disproportionately. These results have
raised the concern that, despite short term physiologic and
metabolic benefits, exercise training could contribute to the
progression of mitochondrial disease by promoting an
increase in mutation levels. Thus the question of whether
training promotes a progressive expansion of mutant
mtDNA needs to be resolved before the basic question of
whether exercise should be encouraged or avoided can be
answered (Taivassalo and Haller, 2004).
A critical corollary question relates to the consequences of
habitual inactivity and to effects of cycles of greater and
lesser regular physical activity levels in patients with mtDNA
mutations. Exercise avoidance results in decreased physical
capacity associated with reduced cardiovascular and skeletal
muscle function in healthy humans and in a variety of
disease states (Saltin and Gollnick, 1983). We have hypo-
thesized that in patients with mitochondrial myopathies,
deconditioning reduces mitochondrial volume, further
restricting the capacity for oxidative phosphorylation and
setting into motion a vicious cycle of worsening exercise
tolerance. However, the physiological effects of decondition-
ing in patients with mitochondrial myopathies have never
been directly assessed, and the critical question of how
inactivity or cycles of greater and lesser physical activity
levels affect the abundance and distribution of mutant versus
wild-type mtDNA in skeletal muscle is currently unknown.
The objectives of this study were to assess the effects of
exercise training and detraining in patients with sporadic
single, large-scale mtDNA deletions. We chose to study these
patients because single large-scale deletions are one of the
most common forms of sporadic mtDNA mutations and
usually result in an exclusively or predominantly skeletal
muscle phenotype. We studied (i) the efficacy and safety of
endurance training (14 weeks) in this patient population;
(ii) the effect of more prolonged (total of 28 weeks) exercise
training upon muscle and cardiovascular function and
(iii) the effect of detraining (14 weeks) upon muscle and
cardiovascular function. In each condition of training,
prolonged training and deconditioning we evaluated
physiological changes as well as effects upon the proportion,
distribution and copy number of mutant and wild-type
mtDNA in skeletal muscle.
Material and methods
Patient description
Eight patients (5 F: 37 6 8 years; 3 M 46 6 11 years) with
molecular evidence of a sporadic single, large-scale deletion of
mtDNA were enrolled in this study (Table 1). Exercise intolerance
was experienced by all patients to a varying degree (mild to severe).
Study design and training protocol
The study was approved by the institutional review boards of
University of Newcastle upon Tyne, University of Texas South-
western Medical Center and Presbyterian Hospital of Dallas. Each
patient was informed of the nature and risks of the study and gave
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their written consent to participate. As shown in the study design
(Fig. 1), all patients underwent heart rate monitored exercise
training on a stationary bicycle for a total of 49 sessions in 14 weeks
(three times per week 1–7, four times per week 8–14). Exercise was
performed at a training intensity corresponding to 70–80% of their
maximal heart rate (determined at baseline as their maximal heart
rate attained during the maximal exercise test) for 30 min per
session for the first 7 weeks and 40 min per session for the last
7 weeks of training. Heart rates and exercise duration were
continuously recorded on a Polar NV chest band and watch,
allowing for subsequent analysis using a Polar/PC computer
interface. Just prior to the 14 weeks evaluation, patients were
randomized to either continue endurance training for an additional
14 weeks (at a training intensity and duration similar to weeks 8
through 14), or stop training and resume pre-study activity levels
for 14 weeks. Exercise testing evaluation and muscle biopsy samples
were obtained at baseline, 14 and 28 weeks.
Exercise testing
Each patient was assessed over a period of 5 days during which time
two different methods of exercise testing were performed: maximal
exercise testing to determine peak exercise capacity and physiolo-
gical response (1 and 5 days); and submaximal exercise to
determine exercise tolerance (day 3). All patients were familiarized
with the experimental setup prior to testing on an electronically
braked, pedal rate-independent cycle ergometer (MedGraphics,
2000). The maximal exercise test was performed twice for
repeatability, and data were averaged (when same peak workload
was reached) or the higher workload of the two is presented. To
ensure exercise testing (and training) did not induce muscle injury,
creatine kinase (CK) levels were monitored prior to testing on day 1
and at the end of the week of testing on day 5.
Maximal exercise testing
As described previously, the workload was increased in 5–10 W
increments every 1–2 min until the patient reached maximal heart
rate (220  age) or exhaustion, usually between 8 and 12 min. Gas
exchange and cardiac output were determined at rest, during one
or more submaximal workloads and with peak exercise. Expired air
was collected in Douglas bags for 120 s at rest and 60 s during
exercise for determination of VO2. The fractions of O2, CO2 and N2
in each bag were analysed with a Marquette 1100 Medical Gas
Analyzer and ventilation was measured with a Tissot spirometer for
calculation of VO2. Cardiac output (Q) was measured utilizing
acetylene rebreathing in which the rate of disappearance of C2H2
from a rebreathing bag is proportional to pulmonary blood flow
and Q. Determination of VO2 and Q allows for the calculation of
systemic arterio-venous oxygen difference, indicated by the Fick
equation: VO2 = Q · systemic a-vO2 difference. DQ/DVO2,
determined by linear regression, was used to assess the relationship
between O2 delivery and uptake. In healthy individuals, irrespective
of age, sex, body weight or level of conditioning, there is a virtual
1:1 relationship between O2 delivery and utilization as indicated
by the fact that Q increases 5 l for each litre of increase in O2
consumption (DQ/DVO2  5) from rest to maximal exercise When
VO2 is limited by impaired muscle oxidative phosphorylation
DQ/DVO2 is characteristically exaggerated (Taivassalo et al., 2003).
Heart rate was continuously monitored during rest and exercise
with a 12-lead electrocardiogram (Quinton 3040 ECG monitor). All
subjects had intravenous catheters inserted in a cubital vein from
which blood was drawn for analysis at rest, various submaximal
exercise levels and at the maximal workload. Whole blood samples
were assayed for lactate using a commercially available analyser
(Yellow Springs Instruments).
At the 14 and 28 week evaluations, the incremental workload
protocol was identical to each patient’s baseline evaluation. If the
end-workload could be surpassed after a period of training, the
exercise intensity was increased until same absolute pre-training
heart rate was attained, and the corresponding maximal workload
and physiological responses were noted.
Submaximal exercise testing
Exercise tolerance was assessed during constant workload exercise.
Patients cycled at a workload corresponding to 60% of the maximal
heart rate measured during the baseline maximal cycle test for
30 min or until exhaustion. Venous blood lactate was sampled at
rest and at 10 min intervals during the exercise, heart rate was
monitored throughout. Also during the test, the subjects’ rating of
exercise effort was obtained at the end of every minute using the
two common Borg scales: the 15-point (ratings between 6 and 20)
for overall body effort; and the 10-point (ratings between 1 and 10)
for leg effort. These validated scales are widely used to gauge ratings
of perceived exertion (RPE) and have been shown to correspond
closely with metabolic and physiologic indices of increasing exercise
intensity (Borg et al., 1985). Testing was repeated using the same
workload as the baseline evaluation at the 14 and 28 week
evaluation.
Table 1 Clinical and genetic characteristics of eight
patients with single, large-scale mtDNA deletions
Patient Age/sex Clinical presentation Size of
mtDNA
deletion (kb)
1 40/F CPEO severe exercise
intolerance, muscle weakness
4.2
2 40/F CPEO, severe exercise
intolerance
5.0
3 40/M CPEO, mild exercise
intolerance
4.8
4 36/F CPEO, exercise intolerance 5.0
5 60/M CPEO, exercise intolerance 3.6
6 45/F CPEO, exercise intolerance,
muscle weakness
4.2
7 25/F CPEO, hearing impairment,
retinitis pigmentosa, exercise
intolerance
3.0
8 40/M CPEO, exercise intolerance 6.0
Fig. 1 Schematic of study design. After 14 weeks of training,
eight patients were randomly selected to undergo continued
training or discontinue training for an additional 14 weeks.
Asterisk denotes evaluation of outcome measures.
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Quality of life
Assessment of the effects of training and detraining on health,
quality of life and physical functioning was obtained by a reliable
and validated survey, the Short Form Health Survey Questionnaire
(SF-36) by the Medical Outcomes Study (Ware and Sherbourne,
1992). This standardized health status auto-assessment was
completed by each patient. Scores of eight different components
of the SF-36 were aggregated and tabulated to give a single physical
component summary score, used to assess the self-determined
improvement with exercise training per patient. The components
reflect physical well-being (physical functioning, role-physical and
bodily pain), psychological well-being (role-emotional and mental
health) and combination of both (general health, vitality and social
functioning). As a point of reference, the score for the general
healthy US population, standardized for age and gender, is 50 6 10.
Muscle needle biopsy
At baseline, 14 weeks of training and after continued training or
detraining, a needle biopsy of the mid-portion of vastus lateralis
muscle was performed to obtain on average a 200 mg sample. These
samples were immediately divided into sections, frozen and stored
in liquid nitrogen for molecular genetic determinations, or frozen
in isopentane cooled by liquid nitrogen for histological and
histocytochemical analysis. Samples for each patient from each time
point (baseline, 14 and 28 weeks) were analysed concurrently.
Histochemistry
Cryostat sections (10 mm) were cut from transversely orientated
muscle blocks. Sections were reacted for both COX and SDH. The
SDH section was used to determine the number of fibres with high
levels of enzyme activity—equivalent to the so-called ‘ragged red’
fibres. Sequential assay of COX and SDH activities was used to
identify COX-deficient fibres (Taylor et al., 2004).
Biochemistry
The activities of the individual respiratory chain complexes I, II and
IV were measured in a post 600gav muscle supernatant and
expressed relative to the activity of the matrix marker enzyme
citrate synthase and to the wet weight of muscle homogenized
(Taylor and Turnbull, 1997).
Mitochondrial DNA studies
The level of deleted mtDNA in each biopsy was determined by
Southern blot analysis of total muscle DNA, the accepted ‘gold
standard’ method for quantifying levels of mtDNA rearrangements.
Briefly, total muscle DNA was digested with either PvuII or with
SnaB1 and probed with a PCR generated probe (15 782–1289 nt)
that hybridize to the non-coding control region (Blakely et al.,
2004). Long-range PCR was used to amplify across the major arc
using primers [L6249 (6249–6265 nt) and H16215 (16 225–16 196
nt), prior to using a panel of M13-tagged PCR primers to
determine the precise deletion breakpoint in each patient.
Sequencing of appropriate PCR products was performed using
BigDye Terminator v3.1 chemistries (Applied Biosystems) on an
ABI 3100 automated DNA sequencer.
Real-time PCR
Fresh frozen muscle sections (20 mm) were mounted on PEN
(polyethylenenaphthalate) slides (Leica Microsystems, Milton
Keynes, UK) and subjected to dual COX/SDH histochemistry as
described above, and air-dried after dehydration. Groups of muscle
fibres (COX-positive, COX-deficient and mixed populations) were
cut into sterile 0.5 ml PCR tubes using a Leica Laser
Microdissection (AS-LMD) System. Following centrifugation
(7000 gav for 10 min), the cells were lysed in 10 ml of cell lysis
buffer [50 mM Tris–HCl (pH 8.5), 1 mM EDTA, 0.5% Tween-20,
200 ng/ml proteinase K] at 55C for 2 h and then 95C for 10 min
to denature the proteinase K. For the studies on COX-positive
and COX-deficient muscle fibres, 20 individual fibres were
microdissected from the section. For the studies on mixed group
of fibres an area (290 000 mm2) was cut from each section. This
represented between 12 and 25 fibres depending on the size of the
fibres, and was cut at random through the section.
Quantitative real-time PCR approach and fluorogenic probes
were used to calculate both the percentage level of deleted mtDNA
and mtDNA copy number. PCR primers and fluorogenic probes
(Applied Biosystems, Warrington, UK) for regions of MTND1
(forward primer, L3485–3504; reverse primer, H3553–3532;
probe, L3506–3529) and MTND4 (forward primer, L12087–
12109; reverse primer, H12170–12140; probe, L12111–12138)
were synthesized, and 5 ml of DNA lysate was amplified separately
with each of the MTND1 and MTND4 primer/probe combinations
as described previously (He et al., 2002; Bender et al., 2006).
Statistical analysis
To evaluate the effects of training in all eight patients, a paired-T
test was performed for comparison at baseline and 14 weeks. To
distinguish the effects of continued training from detraining post-
randomization of the patients into two groups (continued training
and detraining), the difference between 14 and 28 weeks was
calculated per individual in each group and the means of each
group were compared using a two-sample t-test. This enabled the
testing of whether the two groups differed in their response during
the period between 14 and 28 weeks. By utilizing the delta for each
measure, potential bias from the distribution of patients into either
group was avoided. The small sample size per group (n = 4) after
14 weeks lowered the power needed to detect significant differences.
Non-parametric statistics were applied to detect differences in
quality of life scores before and after training
Results
Training compliance
All patients adhered to the training protocol over the
duration of the study. The group of eight patients completed
47 6 4 of the proposed 49 sessions over the 14 week training
period at the intended exercise heart rate intensity, which
corresponded to 75 6 5% of their maximal heart rate
(average maximal heart rate determined at baseline exercise
testing was 172 6 14 b.p.m.). The four patients who conti-
nued training completed 40 6 4 sessions in the subsequent
14 week training period. Furthermore, no exercise-related
injury or complications were experienced as shown by
normal CK levels throughout the training (baseline average
CK: 234 6 236 U/l; 14 weeks training: 211 6 132 U/l; 28
weeks training: 209 6 135 U/l). Exercise testing also had no
effect as revealed by serial CK determinations during the
week of evaluation (baseline: maximal Test 1 = 234 6 236,
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Test 2 = 199 6 211; 14 weeks training: Test 1 = 211 6 132,
Test 2 = 176 6 136; 28 weeks: Test 1 = 209 6 135, Test 2 =
201 6 127 U/l).
Exercise physiology
Training effect
Fourteen weeks of endurance training significantly increased
peak work capacity (26%), peak oxygen uptake (11%), and
peak capacity for oxygen extraction (peak systemic a–v O2
difference, 11%) (Table 2). There was no effect on peak
systemic oxygen delivery (cardiac output, 2%). There was a
trend for normalization of exaggerated cardiac output
relative to oxyen utilization (DQ/DVO2, 11% decrease P =
0.056). Patients also demonstrated an improved capacity for
submaximal exercise, as detected by a 1.3 mM mean
decrease in blood lactate, an 18 b.p.m. decrease in heart rate
(Fig. 2) and significantly lower RPE at the same constant
workload after training (Table 2). Overall, the patients
detected a significant improvement in quality of life after
training with an increase in score (16%) from 37 6 7 to 43
6 7 after training (population norm score 50). The
specific components of the summary score that showed the
greatest improvements were physical functioning (37 6 to
43 6 8, contributing most heavily to physical well-being) as
well as vitality (39 6 13 to 45 6 12) and general heath (33 6
10 to 39 6 10), which contribute equally to both physical
and psychological well-being.
Effects of continued training versus detraining
Effects upon peak work capacity, oxygen utilization and
oxygen extraction differed significantly in the group that
continued training compared to the group that underwent
detraining (Table 3).
Continued training in four patients resulted in the general
maintenance of peak work capacity (115 6 41 W at 14 weeks
to 126 6 44 W at 28 weeks) and peak VO2 (1.69 6 0.45 to
1.72 6 0.45 l/min) and an increase in peak a-vO2 difference
(10.3 6 1.7 to 12.0 6 2.9 md/dl; P < 0.05) (Fig. 3). Likewise,
indices of improved submaximal exercise capacity were
maintained at 28 weeks in this group (Fig. 4); there was no
further decrease in blood lactate (2.3 6 0.8 mM at 14 weeks
to 2.4 6 0.7 mM at 28 weeks) or heart rate (118 6 11 at
14 weeks to 120 6 10 b.p.m. at 28 weeks). Patients’
perception of overall (RPE = 9 6 3 at 14 weeks; 9 6 3 at
28 weeks) and leg effort (RPE = 2 6 2 at 14 weeks; 2 6 1 at
28 weeks) during submaximal exercise did not change.
Quality of life scores remained the same during this period
(43 6 10 at 14 weeks to 43 6 8 at 28 weeks).
Table 2 Physiological effects of 14 weeks of training in
eight patients with mitochondrial myopathy due to single,
large-scale mtDNA deletions
Outcome measure Baseline 14 weeks
Maximal exercise
Peak watts 85.6 6 26 107.5 6 32*
Peak VO2 (l/min) 1.36 6 0.4 1.51 6 0.4*
Peak Q (l/min) 14.4 6 3.9 14.7 6 4.1
Peak A-VO2 diff (mlO2/dl) 9.7 6 2.5 10.8 6 2.7*
DQ/DVO2 8.5 6 2.1 7.6 6 2.8
Submaximal exercise at constant workload
Blood lactate (mM) 3.5 6 0.7 2.2 6 0.6**
Heart rate (b.p.m.) 141 6 17 123 6 16**
RPE (overall body) 13 6 1 9 62**
RPE (leg) 4 6 1 2 6 1*
Quality of life
SF-36 score 37 6 7 43 6 7*
*P < 0.05.
**P < 0.01.
Fig. 2 Changes in blood lactate (left) and heart rate (right) during 30 min of constant workload submaximal exercise before and
after 14 weeks of training in eight mitochondrial myopathy patients.
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Patients who stopped training demonstrated the opposite
response (Fig. 3); there was a mean decrease from the trained
state in peak work (1006 24W at 14 weeks to 786 22W at 28
weeks; P < 0.05), peak VO2 (1.346 0.32 to 1.096 0.32 l/min;
P < 0.05), and peak a-vO2 diff (11.46 3.6 to 10.06 3.7 ml/dl;
P < 0.05). There was a trend for loss of adaptation during
submaximal exercise as evidenced by a 1.1 6 1.0 mM
increase in blood lactate (2.1 6 0.4 to 3.2 6 1.3 mM) and
12 b.p.m. 6 14 increase in heart rate (115 6 2 to 127 6 15)
during constant workload after the cessation of training
Table 3 Comparison of physiological changes after 14 weeks with continued training or discontinued training
Outcome measure Comparison to trained state (D14–28 weeks)
Continued training (n = 4) Detraining (n = 4) Difference between
groups
Peak watts D11 6 10 W D23 6 10 W P = 0.003
Peak VO2 D0.04 6 0.05 l/min D0.25 6 0.12 l/min P = 0.005
Peak A-VO2 D1.7 6 1.7 ml/dl D1.4 6 0.9 ml/dl P = 0.014
Fig. 3 Physiological changes in maximal exercise capacity after 14 weeks of training, followed by further training or
deconditioning, in patients with mitochondrial myopathy.
Fig. 4 Physiological changes in exercise tolerance during submaximal workloads after 14 weeks of training in the two subgroups of
mitochondrial myopathy patients. Note that data shown from the detraining group are for three patients (denoted by #) as one patient was
unable to complete >10 min of submaximal exercise at 28 weeks.
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(Fig. 4). This same absolute workload was perceived by the
patients as requiring greater effort, indicated by increases in
overall body RPE (9 6 2 at 14 weeks; 12 6 3 at 28 weeks)
and leg effort RPE (2 6 1 at 14 weeks; 4 6 2 at 28 weeks).
The group reported a significant decrease in quality of
life after detraining compared to the trained state (43 6 3
before, 35 6 7 after detraining, P < 0.05). As a note, one
patient in this group (Patient 1) injured her knee at the
onset of the detraining phase (unrelated to the previous
exercise training programme) and became significantly
immobile, such that her physical activity was reduced to
levels lower than prior to entry into the study. This patient
was unable to complete >10 min of submaximal exercise at
the 28 week evaluation (Fig. 4).
Interestingly, at the end of detraining, patients in this
group had returned to their baseline with respect to peak
exercise capacity: peak work capacity baseline = 76 6 19 W,
post-detraining = 78 6 22 W; peak oxygen utilization
baseline = 1.12 6 0.28, post-detraining 1.09 6 0.32 l/min;
peak oxygen extraction baseline = 9.7 6 3.3, post-detraining
9.9 6 3.6 ml/dl. The mean submaximal exercise blood
lactate at 28 weeks was equal to that at baseline assessment
(baseline = 3.3 6 0.6, post-detraining 3.2 6 1.3 mM) and
mean submaximal heart rate was slightly lower (baseline =
135 6 6, post-detraining 127 6 15 b.p.m.).
Histochemical analysis of biopsies
After 14 weeks of training there was no significant change in
the percentage of COX-deficient fibres in the 8 patients
overall (19.1 6 12.7 % at baseline, 18.3 6 14.3 at 14 weeks)
Similarly there was no significant change observed in the
percentage of hyper-reactive fibres (5.1 6 6.1% at baseline,
3.1 6 2.3%) after 14 weeks of training. In the group of
patients that continued to train no change in the percentage
of COX-deficient fibres was detected (16.5 6 8.5% at
14 weeks; 18.1 6 7.1% at 28 weeks), whilst in the patients
that stopped training the percentage of COX-deficient fibres
increased from 20 6 19.8% at 14 weeks to 27.4 6 34.9% at
28 weeks, but this increase was entirely due to the results
from Patient 1 (see Discussion).
Biochemical analysis of biopsies
After 14 weeks of training in the eight subjects there was a
trend towards increases in the activity of respiratory chain
complexes compared to the pre-training values (see Fig. 5A),
compatible with previous studies suggesting increased
mitochondrial oxidative activity. Whilst there was consider-
able variation, there was an apparent trend (not significant)
for an increase in citrate synthase activities in the patients
who continued to exercise compared to those who ceased
training (Fig. 5B).
Molecular genetics
Level of mutated mtDNA
In all patients single, large-scale deletions were detected with
no evidence of duplication. Minor variations in levels of
mutant mtDNA were detected in individual patients after
14 weeks of training (five demonstrating a slight decrease,
one a slight increase from pre-training levels, Table 4).
The slight fall in overall level of deleted mtDNA observed
after 14 weeks of training was not significant and within
experimental error (mean level of deletion at baseline =
56 6 19% post-training 53 6 20%). In the group that
continued training the level of deleted mtDNA also did not
change significantly from baseline (56 6 18%) compared to
the level after 28 weeks of training (55 6 23%). Similarly, in
the patient group that stopped training, there was no change
in the level of deleted mtDNA between baseline (55 6 23%),
14 weeks of training (55 6 22%) and at 28 weeks with
detraining (55 6 26%).
Fig. 5 Changes in respiratory chain enzyme complexes I, II and IV and citrate synthase activities with training. (A) The mean change
in the group of eight mitochondrial myopathy patients (6SE) in enzyme activity of biopsy sampled after 14 weeks of training
relative to baseline sample. (B) The mean change in citrate synthase activity in the two subgroups that underwent
continued training or detraining.
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Real-time PCR studies of deletion levels and copy
number
To try to gain further insight into the mechanisms involved
in the effects of exercise on the mitochondrial genome in the
presence of a heteroplasmic mtDNA defect, we also
evaluated the mutation levels and copy number of mtDNA
in collections of COX-deficient, COX-normal or mixed
fibres using a real-time PCR technique. This assay has been
previously validated on muscle and has also proved valuable
in quantifying mtDNA deletions in other tissues (He et al.,
2002; Bender et al., 2006). As one patient in our cohort
(Patient 5) harboured an mtDNA rearrangement in which
the MTND4 gene was not deleted, this patient was excluded
from all real-time analysis. To assess overall copy number in
the biopsy, three samples of mixed fibres were analysed in
triplicate and the mean value determined. The copy number
per unit area did not significantly change after 14 weeks of
training when compared to baseline values (2.2 6 1.0 copies
per mm2 baseline, 2.0 6 0.6 copies after 14 weeks training).
No significant change in copy number was seen after
continued training or detraining (data not shown).
The level of deleted mtDNA in COX-deficient muscle
fibres was significantly different compared to the COX-
normal fibres as would be expected (COX-deficient 98 6
2%; COX-normal 55 6 20% P > 0.001). No change was
observed in the percentage level of deleted mtDNA following
exercise in mixed (baseline 74 6 15%, after training at 14
weeks 73 6 15%), COX-deficient fibres (baseline 98 6 1%,
after 14 weeks training 98 6 1%) or COX-normal fibres
(baseline 57 6 13%, after 14 weeks training 51 6 11%).
Discussion
This study evaluated the effects of training and detraining in
a group of mitochondrial myopathy patients harbouring a
common, sporadic mutation in mtDNA, a single large-scale
deletion. The major findings were that: (i) 14 weeks of
exercise training improved submaximal exercise tolerance
and peak capacity for work, oxygen utilization and skeletal
muscle oxygen extraction with no change in the level of
deleted mtDNA; (ii) continued training for an additional
14 weeks maintained these beneficial adaptations; (iii) the
cessation of training (detraining) resulted in loss of
physiological adaptation to baseline capacity with no overall
change in mutation load as determined by Southern blot and
real-time PCR.
Physiological responses
Effects of 14 weeks of training
The ability of endurance training to improve exercise
capacity and quality of life in patients with mitochondrial
myopathy was confirmed. Training increased peak work
(26%) and oxygen utilization (11%). The dominant physio-
logical mechanism of increased oxygen utilization was an
increase in peak systemic arterio-venous O2 difference
(11%) consistent with an enhanced capacity of muscle
mitochondrial oxidative phosphorylation. As we have
described previously (Taivassalo et al., 2003), the major
physiological manifestation of impaired muscle mitochon-
drial function during exercise in this patient population is a
blunted ability to increase the extraction of oxygen from
blood, as indicated by an abnormally low peak systemic a-
vO2 difference. Conversely, the circulatory response during
exercise is ‘hyperdynamic’, where delivery of oxygen (cardiac
output) is exaggerated relative to oxygen utilization (DQ/
DVO2 > 5). This exercise response contrasts to that of
healthy individuals, in whom systemic a-vO2 difference
increases 3-fold from rest (5 ml/dl) to peak exercise (15
ml/dl), and cardiac output is tightly matched to oxygen
utilization, so that DQ/DVO2 5. Peak baseline exercise and
oxidative capacity of the mitochondrial myopathy patients
was less than half of age-predicted values for sedentary
healthy individuals, but the percentage increase with training
was within the range expected for healthy individuals
undergoing similar training. However, the mechanism
underlying this improvement differs from the training
response in healthy individuals. Normally, increased capacity
for oxygen delivery (cardiac output), is the major physio-
logical basis of improved exercise capacity with training
whereas increases in peak systemic O2 extraction (a-vO2
difference) are relatively minor. In mitochondrial myopathy
patients, we have demonstrated that the mechanism
underlying improved exercise capacity relates predominantly
to improved ability for oxygen extraction by skeletal muscle.
In this study, peak systemic a-vO2 difference increased on
average from 9.7 6 2.5 to 10.8 6 2.7 ml/dl, a result that
closely parallels our previous findings. In contrast to training
effects in healthy subjects, there were no changes in peak
capacity for oxygen delivery over the 14 weeks of training,
with cardiac output remaining remarkably constant (base-
line 14.4 6 3.9; post-training 14.7 6 4.1 l/min).
In addition to improving peak exercise capacity,
endurance training increased patients’ tolerance of submax-
imal exercise. During the same workload after training,
blood lactate levels were 1.3 mM lower, consistent with
enhanced oxidative phosphorylation. The corresponding
Table 4 Percentage of mtDNA deletion as determined by
Southern blot analysis in individual patients at baseline,
following 14 weeks of training and after an additional
14 weeks of training or detraining
Subgroup (14–28 weeks) Patient Baseline 14 weeks 28 weeks
Continued training 2 75 73 76
3 37 28 46
4 67 63 64
5 46 38 33
Discontinued training 1 87 87 87
6 39 39 32
7 55 52 64
8 39 43 37
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heart rate was on average 18 b.p.m. lower, and patients’ per-
ception of effort was reduced. Together, these adaptations
are consistent with a training-induced increase in capacity
for skeletal muscle oxidative phosphorylation and would
be expected to improve patients’ ability to perform activities
of daily living. This notion is supported by patient self
assessment of significantly improved quality of life with
respect to physical well-being, general health and vitality
after training. Findings from the submaximal exercise testing
clearly demonstrate that moderate physical activity is far
better tolerated after training.
The current study extends previous physiological and
molecular findings of endurance training effects in a group
of 10 patients with heterogeneous mtDNA defects, by
focusing on a more homogeneous group of mitochondrial
myopathy patients with a uniform mtDNA molecular defect.
The previous study included only two patients with single
large-scale deletions and the others with various tRNA and
protein-coding mutations (Taivassalo et al., 2001). Patients
in the current study had a lower mean mutation load
(55%) compared to the previous study (65%), with only
3 patients harbouring >65% levels compared with two-third
of the previous subjects having mutation levels >65%.
Accordingly, in the current study, baseline exercise and
oxidative capacity were higher, as was peak systemic a-vO2
difference during cycle exercise, a surrogate marker of
muscle capacity for oxidative phosphorylation (Taivassalo
et al., 2003), (9.7 6 2.5 ml/dl compared to the previous
patient group 6.9 6 2.6). Nevertheless, the magnitude of
improvements in work and oxidative capacity achieved after
endurance training was similar in both studies. Although,
the mean increase in maximal oxygen uptake was 20% in the
previous study (versus 11% in the current study), the
increases in maximal oxidative capacity for the two patients
with single large-scale deletions were 10 and 16%, similar to
our current findings.
Effects of continued training
This phase of the study represents the longest period of
training reported thus far in patients with mitochondrial
myopathy. Although the number of patients studied in this
phase was small, findings indicate that the physiological
benefit of training was maintained through 28 weeks. The
training volume was similar to that of the first 14 weeks of
training, and whether further improvement in exercise
capacity and quality of life might be achieved with more
intense exercise or even a longer period of training awaits
further study.
Effects of detraining
For the first time, the physiological effects of detraining in
mitochondrial myopathies have been quantitatively assessed.
Fourteen weeks of detraining following an equal duration
of training resulted in a loss of beneficial physiological
adaptations. Interestingly, the magnitude of increase from
baseline was equal to the magnitude of decrease from
the trained state. For example, peak work capacity increased
by 24 6 8 W with training, and fell by 23 6 10 W
with detraining, peak oxygen utilization increased 0.22 6
0.17 l/min and decreased 0.25 6 0.12 l/min, and peak
oxygen extraction increased 1.7 6 1.0 ml/dl with training
and decreased 1.5 6 0.9 ml/dl with detraining. At the end
of detraining, patients in this group were back to
their baseline physiological condition. Detrimental effects
of detraining were magnified in one patient who most
dramatically reduced physical activity levels to below
baseline (Patient 1).
Muscle histochemistry, biochemistry and
molecular genetics
Effects of training
The physiological improvements following 14 weeks of
training were associated with a trend toward increases in
citrate synthase and respiratory chain complex activities
which, however, were not as marked as in our previous
study and did not achieve statistical significance. Never-
theless, we consider this trend toward increase oxidative
enzyme activities along with the consistent training related
increase in systemic a-vO2 difference to be compatible with
an increase in muscle capacity for oxidative phosphoryla-
tion. The strength of this study over previous studies is the
homogeneous nature of the genetic defect, but in spite of
this there was considerable difference in the severity of the
biochemical, histochemical and clinical abnormalities.
Improved muscle oxidative capacity was not associated
with increases in the overall percentage of mutant
mtDNA, unlike our previous study in which variable
increases and no decreases in mutant mtDNA were detected
in a heterogeneous group of molecular mtDNA defects,
including two patients with single, large-scale deletions,
raising concern about the safety of endurance training as a
potential therapeutic approach. The minor decreases and
increases in mutant mtDNA detected in the present study
are consistent with expected results from sampling a
heterogeneously distributed mtDNA mutation. In muscle
containing lower overall mutation loads, variability in
mtDNA and COX-deficient fibre content between serial
needle biopsies is expected to be greater than in patients
with higher mutation loads and more uniformly distributed
COX-deficient fibres. Despite the lower mutation load in the
current study and issue of variability, no significant increases
in the level of deleted mtDNA after training were detected.
In addition, no consistent changes in the percentage of
COX-deficient fibres were associated with training. A
previous study has highlighted how difficult it is to accurately
quantify the COX deficiency in both large and small muscle
biopsies (Barron et al., 2005). Variation occurs both between
and within muscle groups, even when counting up to
400 muscle fibres. Our data and those of previous studies
therefore have to be interpreted cautiously.
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We have shown using two different methods (Southern
blotting and real-time PCR) that no increase in the level of
deleted mtDNA following endurance training was detected.
The relative lack of change in mtDNA copy number was
surprising and may relate to the smaller changes in bio-
chemical measures and mitochondrial biogenesis. Whilst
mtDNA copy number correlates with measures of citrate
synthase activity in general (Wang et al., 1999), there are few
studies describing the anticipated effect of endurance
training on the magnitude and relationship between
mtDNA replication, biogenesis and enzyme activity in
healthy humans.
Effects of detraining
There were no consistent changes in the level of deletion or
distribution of COX-deficient fibres with discontinued
training in the group on average. Interestingly however, a
dramatic change was observed was in Patient 1 who
underwent detraining. This patient had 48% COX-deficient
fibres at baseline and after 14 weeks of training, but this
increased markedly when she stopped training to 79%
COX-deficient fibres. A knee injury acquired immediately
post-training, unrelated to exercise, caused this patient to
become significantly immobile and to limit physical activity
to levels below that of her baseline condition. Despite this
extreme form of deconditioning no change was observed
in the percentage of deleted mtDNA in all three biopsies
(87% deleted mtDNA in all three). Of note, however, was
the finding of a 40% decrease in the copy number of total
mtDNA in the COX-deficient fibres in the final biopsy. This
would support evidence that the COX deficiency relates to
the amount of wild-type molecules rather than the total
percentage of mutated mtDNA.
In conclusion, findings from this study provide further
substantial evidence that endurance exercise training has
many potential benefits for patients with mitochondrial
myopathies. The training volume (intensity, frequency and
duration) applied in this study specifically to patients with
single large-scale mtDNA deletions resulted in significant
physiological changes that led to improved maximal and
submaximal exercise capacity and enhanced quality of life.
Furthermore, over the course of a 28 week training period,
we did not detect any evidence of increased mutation load.
Whilst these results are encouraging, we remain cautious
about extending these results to other mtDNA mutations
and advising exercise training as treatment. The lack of more
significant changes in both the biochemical measurements
and copy number of mtDNA with this type of training
protocol warrants further investigation into training-
induced mitochondrial proliferation and effects on mutation
level in single fibres. There is a need for long term studies to
assess whether the physiological benefits can be maintained
over a longer period of time, and more importantly, that no
change in mtDNA mutation load occurs. Our findings on
the effects of detraining clearly implicate physical inactivity
as an important mechanism in reducing exercise capacity
and quality of life in patients with mitochondrial myopathy
and underlie the urgency of clarifying endurance training
effects at the molecular level.
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